ARCHIVES

Guideline Revisions or Outstanding Investigator Grant Still Controversial

This article is from The Cancer Letter archive.

Vol. 09 No. 47 | December 9, 1983

Download PDF Visit The Full Archive

Related Articles

Two Second-Line CML Drugs Work Front-Line, Studies Find

January 29, 2010

NCI Branch Chiefs, ACCI Join Support For DeVita

June 25, 1981

Sexual Function Affected By Stem Cell Transplant

September 28, 2007

UCSF Receives $125 Million Gift for Cancer Hospital

March 27, 2009

NCI Director Klausner Resigns To Head Institute Begun By AOL Chairman Case.

September 14, 2001

HCFA Renamed In HHS Effort At Medicare, Medicaid Reform.

June 22, 2001